Literature DB >> 30199752

hCD46 receptor is not required for measles vaccine Schwarz strain replication in vivo: Type-I IFN is the species barrier in mice.

M Mura1, C Ruffié2, E Billon-Denis1, C Combredet2, J N Tournier1, F Tangy3.   

Abstract

Measles virus has been successfully attenuated on chicken embryo cells to obtain a highly efficient and safe live attenuated vaccine, administered thus far to billions of children. Measles virus attenuation has long been described to involve a modification of cellular tropism with the use of human CD46 ubiquitous receptor. Nevertheless, the use of this receptor in vivo is not obvious. In this study we use four different mouse models to decipher the respective part of hCD46 receptor and type-I interferon response in measles host restriction. We observed that only type-I interferon restricts viral replication of attenuated MV Schwarz strain in mice, independently of the presence of hCD46 receptor. By comparing measles virus immunogenicity in the different models, we confirmed that there was no impact on the absence of this receptor on the immune response. Therefore, we propose to simplify the mouse model.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cellular tropism; Host restriction; Measles live attenuated vaccine; Mouse model; Type-I interferon

Mesh:

Substances:

Year:  2018        PMID: 30199752     DOI: 10.1016/j.virol.2018.08.014

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  5 in total

1.  A Measles Virus-Based Vaccine Candidate Mediates Protection against Zika Virus in an Allogeneic Mouse Pregnancy Model.

Authors:  Cindy Nürnberger; Bianca S Bodmer; Anna H Fiedler; Gülsah Gabriel; Michael D Mühlebach
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

2.  Measles-based Zika vaccine induces long-term immunity and requires NS1 antibodies to protect the female reproductive tract.

Authors:  Drishya Kurup; Christoph Wirblich; Rachael Lambert; Leila Zabihi Diba; Benjamin E Leiby; Matthias J Schnell
Journal:  NPJ Vaccines       Date:  2022-04-19       Impact factor: 9.399

Review 3.  Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines.

Authors:  Aileen Ebenig; Mona V Lange; Michael D Mühlebach
Journal:  NPJ Vaccines       Date:  2022-10-15       Impact factor: 9.399

4.  A highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccine.

Authors:  Cindy Hörner; Christoph Schürmann; Arne Auste; Aileen Ebenig; Samada Muraleedharan; Kenneth H Dinnon; Tatjana Scholz; Maike Herrmann; Barbara S Schnierle; Ralph S Baric; Michael D Mühlebach
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-30       Impact factor: 12.779

5.  A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike.

Authors:  Mijia Lu; Piyush Dravid; Yuexiu Zhang; Sheetal Trivedi; Anzhong Li; Olivia Harder; Mahesh Kc; Supranee Chaiwatpongsakorn; Ashley Zani; Adam Kenney; Cong Zeng; Chuanxi Cai; Chengjin Ye; Xueya Liang; Masako Shimamura; Shan-Lu Liu; Asuncion Mejias; Octavio Ramilo; Prosper N Boyaka; Jianming Qiu; Luis Martinez-Sobrido; Jacob S Yount; Mark E Peeples; Amit Kapoor; Stefan Niewiesk; Jianrong Li
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-23       Impact factor: 12.779

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.